ziprasidone has been researched along with lorazepam in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Coffey, B | 1 |
| Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ | 1 |
| Carnahan, RM; Perry, PJ | 1 |
| Francis, A; Kohen, I; Preval, H; Southard, R | 1 |
| Adams, CE; Jones, H; Powney, MJ | 1 |
| Crittenden, NE; Jortani, SA; Middleberg, RA; Shaw, MA; Truscott, SM | 1 |
| Grabe, HJ; Janowitz, D; Schomerus, G; Speerforck, S | 1 |
| Biros, MH; Cole, JB; Driver, BE; Martel, ML; Miner, JR | 1 |
2 review(s) available for ziprasidone and lorazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles | 2012 |
2 trial(s) available for ziprasidone and lorazepam
| Article | Year |
|---|---|
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
Randomized Double-blind Trial of Intramuscular Droperidol, Ziprasidone, and Lorazepam for Acute Undifferentiated Agitation in the Emergency Department.
Topics: Antipsychotic Agents; Droperidol; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Piperazines; Psychomotor Agitation; Thiazoles | 2021 |
10 other study(ies) available for ziprasidone and lorazepam
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Clinical case presentation: therapeutic challenges in adolescent-onset bipolar disorder.
Topics: Adolescent; Aggression; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clonazepam; Diagnosis, Differential; Education; Family; GABA Modulators; Haloperidol; Hospitalization; Humans; Irritable Mood; Lithium; Lorazepam; Male; Piperazines; Psychiatric Status Rating Scales; Sexual Behavior; Thiazoles; Valproic Acid | 2003 |
Methodological concerns in a trial of ziprasidone and olanzapine.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bias; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lorazepam; Olanzapine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2005 |
Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Databases, Factual; Emergency Medical Services; Emergency Service, Hospital; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Piperazines; Psychomotor Agitation; Retrospective Studies; Thiazoles; Treatment Outcome | 2005 |
Violent behavior and hallucination in a 32-year-old patient.
Topics: Adult; Hallucinations; Humans; Hypnotics and Sedatives; Lorazepam; Male; Piperazines; Thiazoles; Violence | 2013 |
[Psychosis, Intoxication or Serotonin Syndrome? - A 20-Year Old Male with Ziprasidone und Sertraline].
Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lorazepam; Male; Piperazines; Psychotropic Drugs; Schizophrenia, Paranoid; Schizophrenic Psychology; Serotonin Syndrome; Sertraline; Substance-Related Disorders; Thiazoles; Young Adult | 2017 |